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AbstrACt
Objectives Early access to invasive coronary angiography 
and revascularisation for high- risk non- ST elevation 
myocardial infarction (NSTEMI) improves outcomes and is 
supported by current guidelines. We sought to determine 
the most effective criteria at presentation to emergency 
department (ED) to identify high- risk NSTEMI.
setting Secondary care centre northwest England with 
national follow- up.
Participants 1642 consecutive patients (median age 59, 
52% male) presenting to ED with a primary symptom of 
chest pain in whom there is suspicion of NSTEMI.
Primary and secondary measures Multivariate logistic 
regression analysis for the prediction of all- cause death 
(primary) and major adverse cardiac event (MACE defined 
as all- cause death, unplanned coronary revascularisation 
and adjudicated NSTEMI (third universal definition)) 
(secondary measure) at 1 year.
results The incidence of adjudicated NSTEMI was 10.7%, 
and 1- year mortality was 6.3%. Independent predictors 
for all- cause death at 1 year were Global Registry of Acute 
Coronary Events (GRACE) >140, age (per decade increase) 
and high- sensitive cardiac troponin T (hs- cTnT) >50 ng/L. 
hs- cTnT >50 ng/L was associated with adjudicated index 
presentation NSTEMI in the greatest proportion of patients 
(61.7%). When using MACE at 12 months, as opposed to 
all- cause death, as an end point History, ECG, Age, Risk 
factors and Troponin (HEART) score ≥7 was included in 
the multivariate model and had better prediction of index 
NSTEMI than GRACE>140. Combining hs- cTnT >50 ng/L 
and a second independent predictor identified both a high 
proportion of index NSTEMI and elevated risk of all- cause 
death at 1 year.
Conclusions hs- cTnT >50 ng/L or HEART score ≥7 
appear effective strategies to identify high- risk NSTEMI 
at presentation to emergency room with chest pain. 
Multicentre prospective studies enriched with early 
presenters, and with competitor high- sensitive and point- 
of- care troponins, are required to validate and extend 
these findings.
trial registration number NCT02581540.
IntrOduCtIOn
For patients with acute coronary syndrome 
(ACS) without ST elevation, European Society 
of Cardiology guidelines recommend a target 
of performing coronary angiography between 
2 and 72 hours after presentation depending 
on high- risk criteria.1 The evidence is 
derived from a number of studies and meta- 
analyses,2–9 but primarily driven by subgroup 
analysis of the largest study to date examining 
timing of invasive management (TIMing of 
intervention in patients with Acute Coronary 
Syndrome TIMACS study).10 It is important 
to note that all the studies examining early 
versus late angiography for non- ST eleva-
tion myocardial infarction (NSTEMI) took 
place before the high- sensitivity troponin 
era. Biomarker positivity was not mandatory 
for any of the trials, a situation that would 
now be inconsistent with the third universal 
definition of myocardial infarction (MI)11 or 
indeed the recently adopted fourth universal 
definition.11 The timing of early invasive 
(and delayed) cardiac catheterisation varied 
strengths and limitations of this study
 ► This was a large prospective consecutive series of 
patients with suspected acute coronary syndrome.
 ► The diagnosis of myocardial infarction was adjudi-
cated with one hundred percent national follow- up 
for clinically relevant events to 1 year.
 ► The index presentations were to a single centre thus 
limiting external validity.
 ► Presentations were late thus limiting extrapolation 
of findings to very early presenters with chest pain.
 ► Extrapolation to paramedic triage with point- of- 
care troponin is premature due to the differences 
in analytic sensitivity between point- of- care and 
laboratory- based sampling of troponin.
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between studies. Furthermore, some studies10 did not 
supply time from admission to diagnosis of MI.
The challenge for clinical pathways for ACS without ST 
elevation is mainly twofold. First, to diagnose NSTEMI 
early in an ‘undifferentiated’ chest pain population and 
to simultaneously determine risk based on simple criteria. 
Second, mobilisation of resources to organise invasive 
management of appropriately defined high- risk NSTEMI 
in a timely manner is a logistical challenge, particularly if 
coronary intervention is remote from presentation site for 
suspected NSTEMI. Such targets are difficult to achieve 
unless diagnosis and risk stratification are achieved at first 
medical contact (FMC) with direct transfer to the coro-
nary interventional centre.
Risk scores are often used for the purpose of identifying 
high- risk MI and to expedite treatment and in partic-
ular coronary revascularisation. Of the risk scores, the 
History, ECG, Age, Risk factors and Troponin (HEART), 
thrombolysis in myocardial infarction (TIMI) and Global 
Registry of Acute Coronary Events (GRACE) are the most 
widely used from an international perspective and have 
the greatest evidence base.12–14 All of these risk scores have 
troponins embedded as part of the risk equation. It is also 
established that high- sensitive troponin values alone are 
predictive of risk in suspected NSTEMI.15 However, it is 
not clear to what extent high- sensitive troponins or ECGs 
or a range of simple parameters can predict both the 
diagnosis of NSTEMI and the benefit of revascularisation 
at presentation to accident and emergency department 
with chest pain.
We analysed simple predictors of high- risk NSTEMI. 
We also assessed the ability of TIMI, GRACE and History, 
ECG, Age, Risk factors and Troponin (HEART) score to 
identify high- risk NSTEMI from 1642 consecutive (indi-
vidual patient) presentations to emergency room (ER) 
with suspected ACS in a major urban centre.
Methodology
This report details and analyses the high- risk cohort 
from Mersey Acute Coronary syndrome Rule Out Study 
(MACROS)16 to investigate prognostic factors for death 
(from any cause) up to 1 year from presentation to ER with 
suspected ACS. This was a prespecified analysis. MACROS 
is a prospective observational cohort study of consecutive, 
unselected suspected NSTEMI presentations. The defini-
tion of suspected non- ST segment elevation was a primary 
presentation with chest pain and physician decision to 
sample troponin and undertake an ECG at presentation.
The MACROS cohort consists of 1785 consecutive unse-
lected presentations (1642 patients) with chest pain to a 
single major urban hospital (Aintree University Hospitals 
NHS Foundation Trust), between June and November 
2011 (inclusive). For multiple presentations during the 
recruitment period, the first presentation was taken as 
the index entry with subsequent representations, during 
study recruitment, assessed for outcomes. The method-
ology has been extensively detailed.16 Chest pain onset, 
time of presentation and troponin sampling were noted 
during index presentation, to subsequently determine 
interaction of outcomes with time of troponin sampling 
relative to chest pain onset.
The National Health Service (NHS) number was 
recorded for each patient, and outcomes were deter-
mined from Health and Social Care Information Centre 
records of admissions to hospitals in England in the 12 
months following initial presentation. Any patient with 
troponin elevation beyond the 99th percentile (>14 ng/L) 
underwent non- blinded adjudication, by two physicians 
for index presentation MI (using the third universal defi-
nition). For all subsequent admissions with any ischaemic 
heart disease or chest pain, International Classification 
Disease (ICD) codes (online supplementary tables)16 were 
linked by NHS number to any hospital in England. These 
hospitals were contacted for retrieval of clinical records, 
laboratory results, ECGs and cardiac investigations. In 
the event of elevated troponin (biomarker), blinded and 
independent two physician adjudication (with resolution 
by a third in case of disagreement) of MI was undertaken. 
Urgent or emergency revascularisation was adjudicated by 
a single interventional cardiologist. Death was recorded 
from the morbidity and mortality division uploaded from 
the national database of morbidity and mortality. As a 
case ascertainment exercise, to identify cases missed by 
nationally collected ICD-10 codes, all patients were addi-
tionally screened for any coronary revascularisation, 
not identified by ICD-10 coding, in the regional cardio-
thoracic service (serving a population of 2.3 million). 
While all readmissions with elevated troponin were inde-
pendently adjudicated for type 1 MI, index presentations 
were assessed separately but in a non- blinded fashion by 
two physicians.
The dataset has 100% follow- up for up to 1 year with 
full capture of all- cause death, urgent or emergency coro-
nary revascularisation and any chest pain or any isch-
aemic heart disease coded representation (captured for 
adjudication). Table 1 describes the patient population. 
Eighteen variables were selected for univariate analysis 
(table 2). The primary end point used was all- cause death 
at 1 year but MACE (all- cause death, type 1 MI or urgent/
emergency coronary revascularisation) as a secondary 
end point was also evaluated.
TIMI and GRACE scores were determined retrospec-
tively from online calculators by research staff with the 
use of the chest pain proforma, patient record and ambu-
lance proforma alone. To score positively for ST segment 
depression in GRACE and TIMI, planar depression of at 
least 0.5 mm after the J- point was required consistent with 
the Minnesota criteria.17 Calculation of HEART score has 
been detailed in the principal MACROS paper.16 The 
character of chest pain was scored exclusively on the narra-
tive in the patient record and/or chest pain proforma. A 
score of 2 was ascribed when chest pain had documented 
features suggestive of cardiac chest pain and an absence 
of non- specific features. A score of 1 was given if there 
was combination of suspicious and non- specific symptoms 
and a score of 0 was given if there were only non- specific 
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Table 1 Patient population
All Death (6 weeks) Death (1 year)
P values (death 
at 1 year vs all)
Totals 1642 25 104
Age (median (IQR)) 58.8 (47.0–72.3) 74.3 (67.2–87.3) 80.0 (70.2–86.7) <0.001
Sex (male) 858 (52.3%) 13 (52.0%) 55 (52.9%) 0.826
Risk scores
  TIMI (mean (SD)) 1.50 (1.58) 2.00 (1.42) 3.00 (1.60) <0.001
  HEART (mean (SD)) 3.50 (2.30) 6.00 (1.85) 6.00 (2.25) <0.001
  GRACE (mean (SD)) 101.5 (39.6) 158.0 (40.0) 150.5 (35.5) <0.001
Hypertension 695 (42.3%) 16 (64.0%) 63 (60.6%) <0.001
Smoking
  Current 457 (30.3%) 5 (20.0%) 21 (20.2%) 0.750
  Previous 463 (30.7%) 10 (40.0%) 44 (42.3%) 0.750
  Never 589 (39.0%) 9 (36.0%) 32 (30.8%) 0.750
Diabetes mellitus 237 (14.4%) 9 (36.0%) 29 (27.9%) <0.001
Dyslipidaemia 432 (26.3%) 6 (24.0%) 31 (29.8%) 0.408
Family history of premature CAD* 337 (20.6%) 1 (4.0%) 6 (5.8%) 0.693
Previous MI 322 (19.6%) 7 (28.0%) 39 (37.5%) 0.000
Previous PCI 170 (10.4%) 2 (8.0%) 13 (12.5%) 0.471
Previous CABG 91 (5.5%) 1 (4.0%) 12 (11.5%) 0.014
Previous stroke 118 (7.2%) 5 (20.0%) 21 (20.2%) <0.001
Hb (median (IQR)) g/dL 137 (124–148) 121 (103–127) 119 (103–131) <0.001
Creatinine (median (IQR)) mmol/L 91.0 (79.0–105.0) 107.0 (76.0–129.0) 101.5 (76.5–139.0) <0.001
Systolic BP (median (IQR)) 131.0 (118.0–146.0) 119.0 (102.0–129.0) 129.0 (109.0–148.0) 0.114
Heart rate (median (IQR)) 78.0 (67.0–90.0) 108.0 (76.0–121.0) 82.0 (70.5–106.0) <0.001
CP onset/peak to presentation 
(median (IQR)) hours
9.7 (2.4–48.0) 16.2 (3.3–48.0) 6.0 (1.6–36.7) 0.473
Time of chest pain to presentation
  <6 hours 682 (42%) 11 (44.0%) 51 (49.0%) 0.066
  ≥6 hours 946 (58.7%) 13 (52.0%) 51 (49.0%) 0.066
ECG ischaemic† 466 (28%)) 13 (52.0%) 55 (52.9%) <0.001
ST depression ≥0.5 mm 90 (5.5%) 2 (8.0%) 16 (15.4%) <0.001
T- wave abnormalities
Nil 1262 (77.0%) 17 (68.0%) 72 (69.2%) 0.066
Flat 73 (4.5%) 2 (8.0%) 6 (5.8%) 0.066
Biphasic 31 (1.9%) 1 (4.0%) 2 (1.9%) 0.066
Inverted 274 (16.7%) 5 (20.0%) 24 (23.1%) 0.066
Current aspirin use 491 (30.0%) 11 (44.0%) 46 (44.2%) 0.001
*CAD= coronary artery disease. defined as first degree relative with myocardial infarction, or coronary revascularisation under the age of 65
†Definition of ischaemic ECG: atrial fibrillation or atrial flutter with ventricular rate ≥110, other arrhythmia, LBBB, paced rhythm, ST segment 
elevation, ST segment depression, T- wave inversion or T- wave flattening or biphasic T waves in two contiguous leads.
BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CP, chest pain; GRACE, Global Registry of Acute 
Coronary Events; Hb, haemoglobin; HEART, History, ECG, Age, Risk factors and Troponin; LBBB, left bundle branch block; PCI, percutaneous 
coronary intervention; TIMI, thrombolysis in myocardial infarction.
features. Researchers were prompted to grant high suspi-
cion (a score of 2), if there was central chest pain with at 
least one additional feature such as radiation to the arm/
neck/jaw or sweating or relief with glyceryl trinitrate or 
provocation of chest pain with exertion or emotion/stress. 
Largely due to education and widespread dissemination 
of a chest pain proforma prior to study commencement, 
it was possible to score the history component for HEART 
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score for all our patients. Definitions of high- risk scores 
(GRACE >140, TIMI ≥5, HEART ≥7), in terms of numer-
ical values, were accepted definitions of these scores from 
the seminal papers of these respective scores.12 14 18
High-sensitivity cardiac troponin t assay
The assay used was the high- sensitivity troponin T (Roche 
Elecsys). This has been previously evaluated extensively 
and found to fulfil the definition of high sensitivity with 
10% coefficient variation at the 99th percentile.19
Performance of this assay across a number of centres 
has previously been evaluated.19 Analysis was undertaken 
in- house with COBAS e601 analysers using a standard 
18 min assay. Quality control of assay (in- house) at Liver-
pool Clinical laboratories revealed a coefficient of varia-
tion of 11% at low value troponins (<10 ng/L). External 
quality assurance provided by the independent United 
Kingdom National External quality assurance scheme 
(NEQA) revealed interhospital coefficient of variation 
of 10% (SD 0.5) low- level troponin values. Assay perfor-
mance (NEQA) was undertaken monthly throughout the 
duration of the study.
During recruitment of the study, there was a downward 
shift in the Roche Elecsys hs- cTnT that was a result of 
calibration of specific LOTS.20 We recomputed hs- cTnT 
values by adjusting for the shift by reference to local labo-
ratory calibration and that determined by a number of 
groups including the manufacturer.20 21 The adjusted or 
recomputed values were used in the analysis.
Patient and public involvement
The study was formally presented to the SURE group 
at Liverpool Heart and Chest Hospital. This is a patient 
representative body. The patient group endorsed the 
research. They were enthused by the size of the study and 
the comprehensiveness of follow- up. Dissemination of the 
study was suggested to the regional network (Cheshire 
and Mersey Cardiac Network) and patient representative 
bodies, such as SURE, and to media outlets.
The research question was informed partly as a conse-
quence of patient concern of missed MIs and delayed 
definitive treatment to high- risk NSTEMI cases. This 
was particularly relevant as the cardiothoracic centre is 
remote from the receiving centre (emergency depart-
ment (ED) for patients with MI, as is the case in many 
regions in the UK and Europe).
Patients were not involved in the conduct of the study.
statistics
All analyses were performed using Stata V.15.
Cross- tabulations of death at 1 year with elevated 
troponin and ST segment depression were produced, and 
Pearson’s χ2 test performed for categorical variables and 
a two- sample t- test for continuous variables.
Single variable logistic regression models were fitted with 
death at 1 year as outcome. ORs and p values (from like-
lihood ratio (LR) χ2 test compared with the null model) 
are provided. Continuous variables were considered in 
single- variable logistic regression models, and an LR χ2 
test was performed to see if they were significant.
Variables that had p<0.1 in the single- variable logistic 
models were considered for inclusion in the multiple vari-
able model. Inclusion of variables in the model was deter-
mined by backwards selection based on the minimum 
Akaike Information Criterion (AIC), using the swaic 
command in Stata (table 2 details the variables included 
in the multivariate model).
The same procedures for determining multiple variable 
logistic regression models were used for the subgroup 
analysis, which were performed on patients with troponin 
>99th percentile (hs- cTnT >14 ng/L), those with adjudi-
cation of MI or unstable angina at presentation, patients 
not undergoing revascularisation to 1 year and early 
presenters with chest pain.
The composite risk scores included independent vari-
ables such as age and ST depression, which were also 
analysed as independent variables. Therefore, we anal-
ysed variables in the multivariate models to understand if 
apparently independent variables had a correlation coef-
ficient >0.8. The correlation matrices for variables consid-
ered for multivariable models indicated that the largest 
coefficients were <0.6 suggesting appropriateness and 
independence of all factors in the multivariate model.
When making comparisons between hs- cTnT and the 
GRACE score, the result for hs- cTnT was included in the 
composite GRACE score.
Kaplan- Meier survival curves were plotted by GRACE 
score (≤140 and >140) and hs- cTnT (<50 and ≥50 ng/L, 
and single- variable Cox proportional hazards models 
fitted to obtain HRs.
results
The total population was 1642 individual patients who 
presented consecutively with suspected NSTEMI over a 
period of 6 months. Seven hundred five (43%) and 638 
(39%) presented via ambulance (either directly or via 
general practitioner) or self- presented to ER, respectively. 
The median age was 59 (IQR 47–72); 52% were male, 14% 
diabetic, 20% had a history of previous MI; 10% and 6% 
had a history of percutaneous coronary intervention and 
coronary artery bypass surgery, respectively. The median 
time from chest pain to presentation was 9.7 hours (IQR 
2.4-48 hours). Forty- two per cent presented <6 hours from 
onset of chest pain. Four hundred forty- four patients 
(27%) were discharged directly from ED at a median of 
363 min (IQR 271–468 min). Table 1 details the patient 
population, with categorisation by survival status at 6 
weeks and 12 months (see online supplementary table S1 
incorporating MACE at 6 weeks and 12 months). Unsur-
prisingly, patients dead by 1 year were older with higher 
risk scores (HEART, TIMI and GRACE scores). Inter-
estingly, there were strong associations of mortality with 
a previous history of MI, CABG and stroke. In terms of 
presentation, ECG, ST depression but not T- wave changes 
were associated with death at 1 year.
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Table 3 Results of multivariable logistic regression with 
death at 1 year as outcome
Explanatory variable OR (95% CI) P value
GRACE >140 3.50 (1.98 to 6.49) <0.001
Age* 1.71 (1.37 to 2.11) <0.001
hs- cTnT >50 ng/L 1.80 (1.07 to 3.05) 0.028
History of heart failure 1.77 (0.97 to 3.22) 0.062
Diabetes mellitus 1.58 (0.96 to 2.62) 0.075
C- statistic: 0.853
*OR per decade increase in age.
GRACE, Global Registry of Acute Coronary Events; hs- cTnT, high- 
sensitive cardiac troponin T.
Figure 1 A. All- cause death at 1 year by high- sensitive 
cardiac troponin T (hs- cTnT). Kaplan- Meier (KM) survival 
curve by hs- cTnT >50 ng/L HR 5.21 (95% CI 3.45 to 7.88), 
p<0.001. (B) All- cause death at 1 year by Global Registry of 
Acute Coronary Events (GRACE) score. KM survival curve by 
GRACE score, HR 12.43 (95% CI 8.17 to 18.94), p<0.001.
One hundred eighty (11%) were adjudicated as 
suffering from type 1 MI (NSTEMI) and 342 (20.8%) 
with type 1 MI (NSTEMI) or unstable angina (defined as 
patients with normal cardiac troponin levels and typical 
angina at rest, a deterioration of a previously stable 
angina and in cases of positive cardiac exercise testing or 
cardiac catheterisation with coronary arteries found to 
have a stenosis of 70% or greater).
Primary outcome: all-cause death at 1 year
Out of 1642, 104 (6.3%) patients had died at 365 days. 
Table 2 illustrates 18 variables tested for logistic single 
variable regression with death at 1 year as the outcome. 
Descriptions are noted for associations with adjudi-
cated type 1 MI at presentation and urgent or emer-
gency coronary revascularisation up to 6 weeks following 
presentation. The rationale, of the analysis and the data 
presentation, was to identify a single factor or composite 
risk score in a chest pain population that predicted both 
a high percentage of adjudicated MI and was associ-
ated with adverse outcome (higher than average 1- year 
mortality >6.3%).
GRACE score >140 and hs- cTnT >50 ng/L had the 
highest OR for all- cause death at 6 weeks and 1 year. When 
emergency/urgent revascularisation and MI was added 
as an end point to all- cause death (MACE), hs- cTnT 
>100 ng/L and HEART ≥7 had stronger associations 
(online supplementary table S2). GRACE >140 was asso-
ciated with adjudicated NSTEMI in only 29.5% of cases. 
By contrast, an hs- cTnT >50 ng/L was associated with an 
adjudicated index diagnosis of type 1 MI (NSTEMI) in 
61.7% of cases.
Independent predictors of all-cause death
Table 3 illustrates multivariate analysis of predictors 
for death at 1 year. Apart from GRACE >140, no other 
high- risk composite score (HEART ≥7 or TIMI ≥5) 
independently predicted death at 1 year in this popula-
tion. Other factors that were independent predictors at 
1 year for all- cause death were age (per decade increase), 
hs- cTnT >50 ng/L, a history of heart failure and diabetes 
mellitus. ST depression (≥0.5 or ≥1.0 mm) was not 
significantly associated with all- cause death at 1 year in 
multivariate analysis but there are insufficient numbers 
to determine if ≥2 or 3 mm ST segment depression would 
strongly correlate with death at 1 year on multivariate 
analysis. The analysis was repeated without composite 
risk scores (which include elevated troponin, age and 
ECG changes in their composite score). The results were 
consistent with the same independent variables featuring 
in the multivariable model.
Figure 1A,B illustrates Kaplan- Meier curves for GRACE 
score >140 and hs- cTnT >50 ng/L with death to 1 year as 
outcome, with associated HRs.
Sensitivity analyses
We conducted further analyses in subgroups including 
troponin >99th percentile (hs- cTnT >14 ng/L) (n=460 
patients with 78 deaths at 1 year), those with adjudica-
tion of MI or unstable angina at presentation (n=342), 
patients not undergoing revascularisation to 1 year 
(n=1538 with 104 deaths) and early presenters with 
chest pain. Online supplementary table S3 details the 
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findings on multivariate analysis for patients with hs- cTnT 
>14 ng/L. Hs- cTnT >50 ng/L was included as an indepen-
dent predictor using AIC model selection. A history of 
heart failure and diabetes as a comorbid condition were 
independent predictors in this subpopulation. Online 
supplementary table S4 details independent predictors 
for those with adjudicated NSTEMI or unstable angina. 
hs- cTnT was no longer an independent factor. Both the 
subpopulations (hs- cTnT >14 ng/L and adjudicated 
NSTEMI or unstable angina) are likely to dilute the influ-
ence of hs- cTnT on all- cause mortality as both ischaemic 
and non- ischaemic causes of chest pain with elevated 
troponin are strongly linked to adverse outcome. Online 
supplementary table S5 describes the population who did 
not undergo revascularisation (as revascularisation could 
influence prognosis); hs- cTnT >50 ng/L was an indepen-
dent predictor in this cohort. There were insufficient 
events to repeat the analysis with early presenters using 
death alone as an outcome. We determined the interac-
tion of time of chest pain relative to hs- cTnT check and 
the predictors of death in the main multivariate anal-
ysis. There was no interaction of timing of chest pain to 
hs- cTnT check and the fitness of the model for the total 
population or any of the subgroups.
secondary outcome: major adverse outcome events
We also determined the influence of switching the end 
point to 12 months MACE as compared with all- cause 
death. Online supplementary table S6 illustrates the 
results. HEART ≥7 was now included in the model. A 
dissection of the data revealed higher index and subse-
quent MI prediction with HEART ≥7 as compared with 
GRACE >140; 63.3% of patients with HEART ≥7 had MI at 
1 year compared with 32.9% for those with GRACE >140 
(table 2, composite of columns 5 and 6). Twenty- five per 
cent of patients with GRACE score >140 died compared 
with 21.1% of patients with HEART ≥7 (table 2). Inter-
estingly, female gender was protective against MACE 
suggesting lower index MI and coronary revascularisation 
rates.
We analysed the combinations of hs- cTnT >50 ng/L 
at presentation with another independent factor (age 
≥60 and GRACE >140) on multivariate analysis for all- 
cause death (table 4), as well as a range of other factors 
correlating with all- cause death at 1 year. This illustrates 
unsurprisingly the summative effects of this model as 
a predictor of high- risk NSTEMI. Either GRACE >140, 
supra- median age (age ≥60) or HEART ≥7 in combi-
nation with hs- cTnT >50 ng/L identified >55% index 
MI with high short- term (6 weeks) and medium- term 
mortality. One year HEART ≥7+hs- cTnT >50 ng/L 
was associated with revascularisation in nearly 30% of 
patients (almost double compared with GRACE >140). 
The combination of hs- cTnT >50 ng/L and ST depres-
sion had the strongest association with coronary revas-
cularisation, although this constituted only 1.9% of the 
population.
dIsCussIOn
As far as we are aware, no previous work has analysed the 
prognostic impact of a range of simple variables and risk 
scores, at FMC, in a consecutive suspected ACS (ST eleva-
tion excluded) population in the era of high- sensitive 
troponin. The importance of this work is underlined by 
the need for early identification and potential transfer 
of high- risk NSTEMI to a centre capable of undertaking 
early coronary revascularisation.1
This analysis confirms that type 1 MI (NSTEMI) 
represents a fraction of patients presenting to ED with 
chest pain. We have demonstrated that a single hs- cTnT 
>50 ng/L is one effective means of detecting high- risk 
NSTEMI. Over 60% of cases are adjudicated as NSTEMIs 
and there is evidence of an adverse prognostic impact 
both in univariate and multivariate analysis. Indepen-
dent predictors of all- cause mortality (age, GRACE 
>140 and hs- cTnT >50 ng/L) are consistent with find-
ings of individual patient meta- analysis,7 even though 
the meta- analyses were in a confirmed NSTEMI popula-
tion. However, the recently published VERDICT study22 
only found a GRACE score >140 to benefit patients with 
NSTEMI who underwent an early invasive approach. It is 
not clear whether high- sensitive troponins were used in 
all hospitals in Very EaRly versus Deferred Invasive evalu-
ation using Computerized Tomography (VERDICT) and 
second a binary analysis of elevated versus normal troponin 
was used rather than the degree of elevation beyond the 
99th percentile, as in this analysis. It is important to note 
the difference between prognostic impact of a marker and 
the interaction of this marker with proposed interven-
tion to lower risk which could also explain discrepancies 
between our analysis and that of VERDICT. In contrast to 
a confirmed NSTEMI population, ST segment depression 
on ECG was not independently associated with mortality 
at 1 year in our analysis.10
The analysis in table 4 is exploratory and driven by twin 
aims: identification at presentation to ED of a high- risk 
NSTEMI, and capacity of a network to cater for high- risk 
NSTEMI transfers. The combination of hs- cTnT >50 ng/L 
and either age >60 or GRACE score >140 or HEART score 
≥7 identified a very high- risk population and could be 
leveraged depending on agreed definitions of high risk 
and capacity in a network.
The combination of ST depression and hs- cTnT 
>50 ng/L is an attractive proposition in terms of both 
identifying ACS (as opposed to other diagnoses) and 
predicting high- risk status and potential benefit of revas-
cularisation. However, HEART score ≥7 which incorpo-
rates chest pain and ECG and troponin (uniquely for 
risk scores in a semi- quantitative fashion) did not inde-
pendently predict death at 1 year in multivariate anal-
ysis. It did though independently predict MACE due to 
a higher association with index adjudicated MI (table 2). 
GRACE score >140 strongly influences mortality both on 
univariate and multivariate analysis. Less than 30% of 
patients with GRACE >140 had an adjudicated type 1 MI 
thus highlighting the need for combination with another 
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variable such as multiples of hs- cTnT beyond 99th percen-
tile (table 4). It is probable that in an ‘unselected’ popu-
lation with suspected ACS a high GRACE score reflects 
haemodynamic strain caused by several pathologies such 
as pulmonary embolism, myocarditis, cardiomyopathy, 
pneumonia.
The results relate to presentation to ED and further 
work with point- of- care troponins will be required for 
field assessment. The results may not be translatable to 
other high- sensitivity troponins, but we tested the ranges 
(>×3 99th percentile and >×5 99th percentile) to eval-
uate which performs better. Thus, there maybe general 
rules for other populations and differing high- sensitive 
troponins as long as the 99th percentile has been deter-
mined and the analytical precision is consistent with high- 
sensitivity troponin.23
limitations
In an observational study, we cannot impute improved 
prognosis on the basis of associations; either with index 
MI or with revascularisation.
We used all- cause death as an outcome rather than 
cardiac death as incorporated in some studies. This is 
not to imply that high- sensitivity troponin can predict 
non- cardiac death but to accept the uncertainty of cause 
of death, particularly for out- of- hospital deaths and the 
probability of misdiagnosis and therefore miscoding of 
cause of death. Using all- cause death grants a safer esti-
mate of high- risk NSTEMI.
We repeated analysis using MACE. The results of the 
logistic regression analysis and the best- fit model for 
multivariate independent predictors revealed a strongly 
positive result for HEART ≥7, which supplanted GRACE 
>140. While HEART ≥7 predicted MI better than GRACE 
>140, it was less often associated with death. This illus-
trates an important limitation in interpretation of data. 
While HEART ≥7 most likely predicted cardiovascular 
death (subsequent to MI), GRACE >140 was most likely 
predictive of non- cardiovascular death. The dynamics 
and multivariable model could be different if cardiac 
death was the end point. However, in a real- world setting 
with a substantial proportion of out- of- hospital deaths 
and a low post- mortem rate it may not be possible to 
distinguish between cardiac and non- cardiac deaths with 
any reasonable certainty. From a pragmatic point of view, 
high HEART score maybe preferable to GRACE as a 
comparison of risk scores alone as it is more likely to be 
associated with possibilities of coronary revascularisation 
and thus an improvement in prognosis.
Presentations were late in this cohort and early 
presenters may diminish the ‘performance’ of point- of- 
care troponin. Furthermore, there was delay in testing 
hs- cTnT (median 166 min) potentially overestimating the 
positive predictive value of hs- cTnT >50 ng/L for a diag-
nosis of MI. However, we found no interaction in outcome 
(multivariable analysis) with time of chest pain relative to 
admission. Further analysis in a cohort enriched with early 
presenters and earlier sampling of hs- cTnT is warranted 
to confirm these results.
Although follow- up was nationwide (eight hospitals 
with representations with chest pain/ischaemic heart 
disease code extracted for adjudication), presentations 
were to a single centre thus limiting its external validity.
COnClusIOn
hs- cTnT >50 ng/L alone, or in combination with an addi-
tional independent predictor, in the context of suspected 
ACS, appears an effective strategy to identify high- risk 
NSTEMI. Analyses with early presenting cohorts are 
necessary to extend these results.
Interpretation
The findings of this analysis could help inform NSTEMI 
pathways and reduce mortality for high- risk NSTEMI by 
earlier redirection for revascularisation. However, such 
a strategy needs testing in a separate analysis to specifi-
cally determine if this change to cardiac pathways leads 
to improved prognosis. It is also important to point out 
that in the event of redirection to a centre with coronary 
revascularisation facilities, there is potential for dramatic 
reduction on length of stay.
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